US FDA 'Bulks Up' 503B Outsourcing Drug List By Proposing Four First-Time Additions
Executive Summary
The US FDA has proposed allowing outsourcing facilities to compound from four drug substances, but not from 19 others that it says already are available in FDA-approved drug products. Compounding pharmacies also would be allowed to compound from two of the four drug substances.